HomeMOLN • NASDAQ
Molecular Partners AG
add
Market news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (CHF) | Jun 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 3.99M | -10.05% |
Net income | -20.40M | -35.25% |
Net profit margin | — | — |
Earnings per share | -0.56 | — |
EBITDA | -14.15M | 7.98% |
Effective tax rate | — | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (CHF) | Jun 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 114.49M | -28.05% |
Total assets | 124.25M | -27.17% |
Total liabilities | 17.59M | 16.89% |
Total equity | 106.66M | — |
Shares outstanding | 37.39M | — |
Price to book | 1.29 | — |
Return on assets | -27.70% | — |
Return on capital | -30.77% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (CHF) | Jun 2025info | Y/Y change |
|---|---|---|
Net income | -20.40M | -35.25% |
Cash from operations | -13.10M | 16.68% |
Cash from investing | 14.97M | 13.85% |
Cash from financing | -243.00K | 8.99% |
Net change in cash | 603.00K | 122.68% |
Free cash flow | -3.61M | 63.16% |
Previous close
$3.67
Year range
$3.36 - $7.60
Market cap
143.72M USD
Avg Volume
4.33K
P/E ratio
-
Dividend yield
-
About
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Founded
2004
Website
Employees
153
